Eastgate Biotech Corp. Stock

Equities

ETBI

US2772531008

Pharmaceuticals

Market Closed - OTC Markets 09:54:04 2024-04-30 EDT 5-day change 1st Jan Change
0.009 USD +28.57% Intraday chart for Eastgate Biotech Corp. -.--% -10.00%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2015 0.13 0.18 Sales 2016 - Capitalization 9.82M 13.42M
Net income 2015 -4M -5.47M Net income 2016 -2M -2.73M EV / Sales 2015 52,069,161 x
Net Debt 2015 1.35M 1.84M Net Debt 2016 1.72M 2.35M EV / Sales 2016 -
P/E ratio 2015
-0.85 x
P/E ratio 2016
-3.28 x
Employees 3
Yield 2015 *
-
Yield 2016
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart
EastGate Biotech Corp., Dr. Upadhyay Vedic Research Laboratories and ImmunoJuvenate, Inc. Enter Into a 3-way International Distribution Agreement CI
EastGate Biotech Corp. Enters into A Licensing and Distribution Agreement for Glucora CI
EastGate Biotech Corp. and EastGate Biotech Pakistan Expands its Collaboration in Advancing the Development of a New Vaccine Against COVID-19 CI
Eastgate Biotech Corp. Announces Phase 3 Clinical Trials of Insurgin CI
EastGate Biotech Corp. Partners with EastGate Biotech Pakistan for the International Marketing Rights of Anaferon CI
EastGate Biotech Corp Expands Pipeline to Alzheimer’S Disease Using Its Alternative Insulin Delivery Platform CI
Eastgate Biotech Corp. Announces Expansion and Restructuring of Joint Venture with Its Partner in Pakistan CI
EastGate Biotech Receives Regulatory Approval to Initiate a Phase III 90-day Clinical Trial on Insugin, Its Liquid Insulin Mouth Rinse Solution CI
Eastgate Biotech Corp. Appoints Bill Abajian as Chief Operating Officer CI
EastGate Biotech Corp Announces It Has Filed an Application with the Drug Regulatory Authority of Pakistan and Ministry of National Health Services to Initiate A Phase Iii Clinical Study for Insugin CI
Eastgate Biotech Announces Preparation to Initiate Phase III Clinical Trials on Insugin CI
EastGate Biotech Announces Positive Phase II Clinical Results of its Innovative Liquid Insulin Mouth Rinse Solution for Type 2 Diabetes CI
Eastgate Biotech Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2017 CI
EastGate Biotech Enters into Licensing Agreement with Nico Innovapharma CI
Eastgate Biotech Corp. announced that it expects to receive $2 million in funding from Nico Innovagroup S.r.l. CI
More news
1 day+28.57%
1 month+12.50%
6 months-10.00%
Current year-10.00%
More quotes
1 month
0.01
Extreme 0.007
0.01
Current year
0.00
Extreme 0
0.01
1 year
0.00
Extreme 0
0.01
3 years
0.00
Extreme 0
0.01
5 years
0.00
Extreme 0
0.03
10 years
0.00
Extreme 0
0.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 15-01-14
President 66 16-05-31
Chief Tech/Sci/R&D Officer - 17-04-11
Members of the board TitleAgeSince
Director/Board Member 68 12-05-21
Chief Executive Officer 55 15-01-14
More insiders
EastGate Biotech Corp. is a pharmaceutical company. The Company produces and distributes nutraceuticals that are based on natural therapies and absorbed naturally by the body. The Company utilizes nanotechnologies to deliver healthy alternatives to conventional pharmaceuticals that all too often create dangerous side effects and unexpected consequences for those trying to attain and maintain healthy lives. The Company’s products include E-Drops NANO, Essential D, GluCora, VCleanzz, Cleanezze and Warts X. The Company also develops products in which the components are incorporated into vehicles containing nano-sized delivery vectors, including oil droplets (nanoemulsions), polymeric particles (nanoparticles) and the combination of polymers and lipids with surfactants (hybrid nanoparticles, nanocapsules, mixed micelles).
More about the company
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW